Stock Ideas
Stocks
Funds
Screener
Sectors
Watchlists
ARCT

ARCT - Arcturus Therapeutics Holdings Inc Stock Price, Fair Value and News

27.44USD-0.01 (-0.04%)Delayed as of 24 Jun 2024, 12:01 pm ET

Market Summary

ARCT
USD27.44-0.01
Delayedas of 24 Jun 2024, 12:01 pm
-0.04%

ARCT Alerts

  • 2 major insider sales recently.
  • Big fall in Revenue (Y/Y)
  • Big fall in earnings (Y/Y)
  • Losses in recent quarter

ARCT Stock Price

View Fullscreen

ARCT RSI Chart

ARCT Valuation

Market Cap

739.3M

Price/Earnings (Trailing)

-6.89

Price/Sales (Trailing)

5.94

EV/EBITDA

-4.52

Price/Free Cashflow

75.71

ARCT Price/Sales (Trailing)

ARCT Profitability

EBT Margin

-84.48%

Return on Equity

-40.65%

Return on Assets

-25.62%

Free Cashflow Yield

1.32%

ARCT Fundamentals

ARCT Revenue

Revenue (TTM)

124.5M

Rev. Growth (Yr)

-52.65%

Rev. Growth (Qtr)

23.2%

ARCT Earnings

Earnings (TTM)

-107.3M

Earnings Growth (Yr)

-152.84%

Earnings Growth (Qtr)

-129.07%

Breaking Down ARCT Revenue

52 Week Range

23.5237.75
(Low)(High)

Last 7 days

-11.5%

Last 30 days

-15.3%

Last 90 days

-19.1%

Trailing 12 Months

11.4%

How does ARCT drawdown profile look like?

ARCT Financial Health

Current Ratio

3.26

Debt/Equity

0.08

Debt/Cashflow

0.61

ARCT Investor Care

Shares Dilution (1Y)

1.39%

Diluted EPS (TTM)

-4.01

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
2024124.5M000
2023281.0M264.5M296.2M166.8M
202215.5M40.6M51.5M206.0M
20219.0M8.7M8.8M12.4M
202019.1M11.3M10.3M9.5M
201917.0M18.3M19.5M20.8M
201800015.8M
GRUFITY'S FAIR VALUE MODEL

Stocks Marked 'Very Cheap' by Grufity's Fair Value Model Have Outperformed Russell 2000 Index

Small Caps and Mid Caps are mostly overlooked by investors as all the focus goes to Magnificent 7. These stocks that are not part of the beauty contest require a deeper look. However, all large cap stocks were once small caps. Grufity's Fair Value model opens up this unverse as it separates high-performing, rewarding stocks from low-performing risky stocks. <b>Russell 2000 stocks that were marked 'Very Cheap' by the model doubled in three years while the index was flat.</b>

PurpleZone


Returns of $10,000 invested in:

Very Cheap Stocks: $21,859
Russell 2000 Index: $10,334
Very Expensive Stocks: $8,224


Russell 2000 stocks considered 'Very Cheap' by the model greatly outperformed Russell 2000 index and the 'Very Expensive' bucket over past three years.

Russell 2000 Index
Very Expensive Stocks
Very Cheap Stocks
Try For Just $1.99

Tracking the Latest Insider Buys and Sells of Arcturus Therapeutics Holdings Inc

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Jun 14, 2024
marantz jing l.
acquired
-
-
3,131
-
Jun 14, 2024
markels john
acquired
-
-
3,131
-
Jun 14, 2024
marquet magda
acquired
-
-
3,131
-
Jun 14, 2024
holmes edward w
acquired
-
-
3,131
-
Jun 14, 2024
barlow james f
acquired
-
-
3,131
-
Jun 14, 2024
farrell peter c
acquired
-
-
3,131
-
Jun 12, 2024
sassine andy
sold
-1,601,500
32.03
-50,000
chief financial officer
Jun 05, 2024
chivukula pad
sold
-5,130
45.00
-114
chief scientific officer & coo
Jun 03, 2024
chivukula pad
sold
-1,040,230
40.009
-26,000
chief scientific officer & coo
Mar 25, 2024
chivukula pad
sold
-610,574
35.02
-17,435
chief scientific officer & coo

1–10 of 50

Which funds bought or sold ARCT recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
Jun 21, 2024
Abich Financial Wealth Management LLC
new
-
101
101
-%
Jun 04, 2024
DekaBank Deutsche Girozentrale
unchanged
-
9,000
1,410,000
-%
May 28, 2024
Boston Partners
new
-
579,800
579,800
-%
May 28, 2024
TEACHERS RETIREMENT SYSTEM OF THE STATE OF KENTUCKY
new
-
517,000
517,000
-%
May 21, 2024
China Universal Asset Management Co., Ltd.
added
66.82
77,017
174,017
0.02%
May 16, 2024
CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM
reduced
-4.77
15,866
809,602
-%
May 16, 2024
JANE STREET GROUP, LLC
reduced
-32.99
-635,074
1,614,780
-%
May 16, 2024
Tidal Investments LLC
new
-
232,236
232,236
-%
May 16, 2024
COMERICA BANK
added
21.16
6,577
28,779
-%
May 15, 2024
Schonfeld Strategic Advisors LLC
reduced
-13.7
-957,594
11,701,100
0.08%

1–10 of 43

Are Funds Buying or Selling ARCT?

Are funds buying ARCT calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own ARCT
No. of Funds

Unveiling Arcturus Therapeutics Holdings Inc's Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Apr 05, 2024
blackrock inc.
10.2%
2,743,002
SC 13G/A
Feb 13, 2024
vanguard group inc
5.46%
1,458,380
SC 13G/A
Feb 12, 2024
nikko asset management americas, inc.
4.94%
1,320,652
SC 13G/A
Feb 05, 2024
sumitomo mitsui trust holdings, inc.
4.94%
1,320,652
SC 13G/A
Jan 29, 2024
ark investment management llc
7.66%
2,047,687
SC 13G/A
Jan 25, 2024
blackrock inc.
9.0%
2,398,296
SC 13G/A
Jan 25, 2024
state street corp
6.10%
1,629,666
SC 13G/A
Jan 17, 2024
federated hermes, inc.
17.63%
4,711,512
SC 13G/A
Oct 10, 2023
state street corp
6.27%
1,667,925
SC 13G/A
Feb 10, 2023
nikko asset management americas, inc.
5.45%
1,449,060
SC 13G/A

Recent SEC filings of Arcturus Therapeutics Holdings Inc

View All Filings
Date Filed Form Type Document
Jun 21, 2024
3
Insider Trading
Jun 21, 2024
4
Insider Trading
Jun 18, 2024
144
Notice of Insider Sale Intent
Jun 18, 2024
4
Insider Trading
Jun 18, 2024
4
Insider Trading
Jun 18, 2024
4
Insider Trading
Jun 18, 2024
4
Insider Trading
Jun 18, 2024
4
Insider Trading
Jun 18, 2024
4
Insider Trading
Jun 14, 2024
4
Insider Trading

Peers (Alternatives to Arcturus Therapeutics Holdings Inc)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
51.1B
6.8B
-18.41% 10.61%
-8.56
7.46
-64.45% -224.75%
22.5B
216.3K
-0.77% 465779.94%
-2.5K
104.0K
- -8.13%
21.0B
2.0B
9.73% -16.82%
-63.12
10.46
75.20% 68.82%
15.9B
2.5B
9.61% -12.35%
77.43
6.44
13.74% 186.89%
14.2B
3.8B
8.63% 2.12%
19.04
3.77
8.58% 129.81%
MID-CAP
5.1B
107.9M
-6.63% 69.33%
-9.37
48.09
54.84% -28.31%
4.6B
524.1M
-12.71% -56.08%
-11.07
8.82
394.93% 39.61%
3.6B
251.0M
-0.36% -15.32%
-12.24
14.45
73.58% -86.73%
3.2B
240.7M
1.47% -28.24%
-6.69
12.77
-1.03% -213.92%
2.5B
813.8M
-3.10% -36.23%
-1.5K
3.11
56.43% 98.83%
2.0B
996.6M
-10.70% 95.81%
-4.94
1.98
-26.66% 65.49%
SMALL-CAP
1.8B
411.3M
-3.41% 18.74%
28.28
4.48
60.38% -34.49%
453.7M
881.7K
-5.58% 440.76%
-13.44
481.06
-77.61% 33.36%
209.4M
4.2M
-28.18% 49.63%
-1.68
50.33
-66.30% 48.24%
18.2M
2.1M
-6.22% 224.62%
-0.79
7.61
-13.45% 69.54%

Arcturus Therapeutics Holdings Inc News

Latest updates
Simply Wall St19 Jun 202412:51 pm
Defense World19 Jun 202411:08 am
Defense World16 Jun 202407:51 am
Seeking Alpha07 Jun 202407:00 am

Arcturus Therapeutics Holdings Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
Income Statement (Quarterly)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Revenue23.2%38,012,00030,855,00045,140,00010,519,00080,285,000160,293,00013,369,00027,093,0005,244,0005,794,0002,437,0002,001,0002,127,0002,238,0002,333,0002,322,0002,646,0002,968,0003,318,00010,153,0004,350,000
Operating Expenses39.3%68,424,00049,127,00064,454,00065,893,00065,530,00038,841,00050,176,00049,182,00055,623,00043,439,00056,258,00055,721,00059,793,00033,320,00023,271,00012,364,00012,108,00013,785,00010,934,00010,725,00010,858,000
  S&GA Expenses18.7%14,851,00012,507,00013,377,00013,225,00013,762,00011,860,00012,488,00010,993,00010,730,00010,806,00010,860,00010,042,0009,743,0009,034,0005,572,0004,420,0004,191,0001,791,0003,881,0003,456,0003,534,000
  R&D Expenses46.3%53,573,00036,620,00051,077,00052,668,00051,768,00026,981,00037,688,00038,189,00044,893,00032,633,00045,398,00045,679,00050,050,00024,286,00017,699,0007,944,0007,917,00011,994,0007,053,0007,269,0007,324,000
EBITDA Margin-485.5%-0.80-0.140.360.330.420.06-3.91-4.97-13.04-16.33-----------
Interest Expenses-100.0%-25,000--2,102,000228,000230,000186,000169,000170,000173,000172,000169,000578,000-7,000-48,000228,000183,000168,000173,000167,000
Income Taxes57.6%368,000233,500900,000600,000103,000---100,000------------
Earnings Before Taxes-131.1%-26,449,000-11,445,000-15,329,000-51,973,00050,857,000118,642,000-35,266,000-21,563,000-51,169,000------------
EBT Margin-405.2%-0.84-0.170.340.310.400.05-3.95-5.02-13.16-16.48-----------
Net Income-129.1%-26,817,000-11,707,000-16,222,000-52,550,00050,754,000117,347,000-35,266,000-21,563,000-51,169,000-38,663,000-54,084,000-54,581,000-56,346,000-31,104,000-21,004,000-10,263,000-9,777,000-10,989,000-7,433,000-685,000-6,884,000
Net Income Margin-383.5%-0.86-0.180.340.300.400.05-2.85-4.08-12.83-16.48-22.28-18.74-13.16--------
Free Cashflow-285.4%-5,797,000-1,504,000-33,387,00050,453,000-36,562,000156,452,000-44,592,000-36,443,000-51,150,000-43,615,000-18,419,000-33,347,000-43,068,000--------
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22018Q4
Assets-2.5%41942945843147145029433734239343544948147632315072.0082.0087.0071.0044.00
  Current Assets-2.8%37638739338542540324729232737942143847046831414264.0074.0079.0063.0042.00
    Cash Equivalents-1.2%28829231232332839423828332037041443446746330713659.0071.0074.0056.0037.00
  Net PPE-5.3%12.0012.0013.0013.0013.0012.0011.009.008.006.005.003.003.003.003.003.003.002.002.002.002.00
Liabilities2.6%15515117814514218014816615716517514312980.0061.0057.0055.0056.0051.0049.0031.00
  Current Liabilities40.8%11582.0088.0090.0090.0012776.0093.0010710011871.0053.0050.0028.0023.0022.0021.0022.0016.0013.00
  Long Term Debt---20.00---32.0036.0039.0041.0042.0056.0058.0014.0015.0015.0015.0015.0010.0010.0010.00
    LT Debt, Current------61.0028.0027.0024.0022.00---1.00-------
    LT Debt, Non Current---20.00---32.0036.0039.0041.0042.0056.0058.0014.0015.0015.0015.0015.0010.0010.0010.00
Shareholder's Equity-5.2%26427928028532927014617118522825930635339726293.0017.0026.0036.0022.0014.00
  Retained Earnings-7.3%-394-367-356-339-287-338-455-420-398-347-308-254-200-143-112-91.71-81.44-71.67-60.68-53.25-44.87
  Additional Paid-In Capital1.9%65964663662561760860159158357656856055354037418598.0097.0097.0075.0058.00
Shares Outstanding0.3%27.0027.0027.0027.0027.0027.0026.0026.0026.0026.0026.0026.00---------
Float----692---376---700---701---76.00-
Cashflow (Last 12 Months)
(In Thousands)
Cashflow (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Cashflow From Operations-783.5%-5,557-629-32,40650,807-35,871160,259-42,406-36,821-49,039-42,497-16,653-32,943-42,950-6,632-15,877-8,494-11,858-7,538-2,8369,340-5,411
  Share Based Compensation14.4%10,0888,8159,2698,3838,1826,5309,4367,2747,3717,5186,8707,5406,9872,8261,9881,101849797383403399
Cashflow From Investing72.6%-240-875-981-354-691-3,807-2,186378-2,111-1,118-1,766-404-118-697-434-469-142-315-159-266-78.00
Cashflow From Financing111.7%2,188-18,65721,84094.00-27,364-2,232-1,22025733623069282.0047,012163,201187,22385,6031185,03421,327--
Get Full Access to Grufity – and Unlimited Downloads
Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.
Try For Just $1.99

ARCT Income Statement

2024-03-31
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($)
shares in Thousands, $ in Thousands
3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Revenue:  
Total revenue$ 38,012$ 80,285
Operating expenses:  
Research and development, net53,57351,768
General and administrative14,85113,762
Total operating expenses68,42465,530
(Loss) income from operations(30,412)14,755
Loss from foreign currency(53)(328)
Gain on debt extinguishment 33,953
Finance income, net4,0162,477
Net (loss) income before income taxes(26,449)50,857
Provision for income taxes368103
Net (loss) income$ (26,817)$ 50,754
(Loss) earnings per share  
Basic$ (1)$ 1.91
Diluted$ (1)$ 1.87
Weighted-average shares used in calculation of (loss) earnings per share:  
Basic26,87926,555
Diluted26,87927,149
Comprehensive (loss) income:  
Net (loss) income$ (26,817)$ 50,754
Comprehensive (loss) income(26,817)50,754
Collaboration Revenue [Member]  
Revenue:  
Total revenue32,59879,729
Grant Revenue [Member]  
Revenue:  
Total revenue$ 5,414$ 556

ARCT Balance Sheet

2024-03-31
CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)
$ in Thousands
Mar. 31, 2024
Dec. 31, 2023
Current assets:  
Cash and cash equivalents$ 288,396$ 292,005
Restricted cash55,00055,000
Accounts receivable27,05732,064
Prepaid expenses and other current assets5,3357,521
Total current assets375,788386,590
Property and equipment, net11,76312,427
Operating lease right-of-use asset, net29,41328,500
Non-current restricted cash1,8851,885
Total assets418,849429,402
Current liabilities:  
Accounts payable9,1445,279
Accrued liabilities34,77031,881
Deferred revenue71,51644,829
Total current liabilities115,43081,989
Deferred revenue, net of current portion11,79542,496
Operating lease liability, net of current portion27,65225,907
Other non-current liabilities 497
Total liabilities154,877150,889
Stockholders’ equity  
Common stock, $0.001 par value; 60,000 shares authorized; issued and outstanding shares were 26,917 at March 31, 2024 and 26,828 at December 31, 20232727
Additional paid-in capital658,628646,352
Accumulated deficit(394,683)(367,866)
Total stockholders’ equity263,972278,513
Total liabilities and stockholders’ equity$ 418,849$ 429,402
ARCT
Arcturus Therapeutics Holdings Inc., a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA. The company is developing ARCT-810 (LUNAR-OTC), a mRNA-based therapeutic candidate, which is in Phase 2 clinical trial for treating ornithine transcarbamylase deficiency; and ARCT-154 (LUNAR-COV19), a mRNA vaccine candidate that is in Phase 3 arm of a Phase 1/2/3 study in Vietnam for the treatment of COVID-19, as well as ARCT-032 (LUNAR-CF), a mRNA therapeutic candidate for cystic fibrosis. The company was founded in 2013 and is headquartered in San Diego, California.
 CEO
 WEBSITEhttps://arcturusrx.com
 INDUSTRYBiotechnology
 EMPLOYEES170

Arcturus Therapeutics Holdings Inc Frequently Asked Questions


What is the ticker symbol for Arcturus Therapeutics Holdings Inc? What does ARCT stand for in stocks?

ARCT is the stock ticker symbol of Arcturus Therapeutics Holdings Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Arcturus Therapeutics Holdings Inc (ARCT)?

As of Fri Jun 21 2024, market cap of Arcturus Therapeutics Holdings Inc is 739.28 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of ARCT stock?

You can check ARCT's fair value in chart for subscribers.

What is the fair value of ARCT stock?

You can check ARCT's fair value in chart for subscribers. The fair value of Arcturus Therapeutics Holdings Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Arcturus Therapeutics Holdings Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for ARCT so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Arcturus Therapeutics Holdings Inc a good stock to buy?

The fair value guage provides a quick view whether ARCT is over valued or under valued. Whether Arcturus Therapeutics Holdings Inc is cheap or expensive depends on the assumptions which impact Arcturus Therapeutics Holdings Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for ARCT.

What is Arcturus Therapeutics Holdings Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Jun 21 2024, ARCT's PE ratio (Price to Earnings) is -6.89 and Price to Sales (PS) ratio is 5.94. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. ARCT PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Arcturus Therapeutics Holdings Inc's stock?

In the past 10 years, Arcturus Therapeutics Holdings Inc has provided -0.139 (multiply by 100 for percentage) rate of return.